TY - JOUR
T1 - From the gut to the strut
T2 - Where inflammation reigns, bone abstains
AU - Iqbal, Jameel
AU - Yuen, Tony
AU - Sun, Li
AU - Zaidi, Mone
N1 - Funding Information:
M. Zaidi is/has been a consultant for Merck, Novartis, Roche, Gerson Lehmann Group, and Guidepoint. He will be entitled to proceeds from any licensing agreement between Icahn School of Medicine at Mount Sinai and any commercial entity for a US patent relating to the use of follicle-stimulating hormone (FSH) blockers in preventing bone loss. M. Zaidi acknowledges the NIH for support (AG40132, AG23176, AR65932, and AR67066).
Publisher Copyright:
© 2016, American Society for Clinical Investigation. All rights reserved.
PY - 2016/6/1
Y1 - 2016/6/1
N2 - In this issue of the JCI, Li et al. show that germ-free mice, when chemically castrated, do not lose bone - a finding that unequivocally establishes a role of gut microbiota in mediating hypogonadal bone loss. Additionally and not unexpectedly, probiotics reversed hypogonadal osteopenia in sex steroid-deficient mice by preventing the disruption of gut barrier function and dampening cytokine-induced inflammation. The authors propose that TNFα is a key mediator; however, it is very likely that other molecules - including IL-1, IL-6, IL-17, RANKL, OPG, and CCL2 - modulate probiotic action. The results of this study highlight the potential for repurposing probiotics for the therapy of osteoporosis. Future placebo-controlled clinical trials will be required to establish safety and efficacy of probiotics in reducing fracture risk in people.
AB - In this issue of the JCI, Li et al. show that germ-free mice, when chemically castrated, do not lose bone - a finding that unequivocally establishes a role of gut microbiota in mediating hypogonadal bone loss. Additionally and not unexpectedly, probiotics reversed hypogonadal osteopenia in sex steroid-deficient mice by preventing the disruption of gut barrier function and dampening cytokine-induced inflammation. The authors propose that TNFα is a key mediator; however, it is very likely that other molecules - including IL-1, IL-6, IL-17, RANKL, OPG, and CCL2 - modulate probiotic action. The results of this study highlight the potential for repurposing probiotics for the therapy of osteoporosis. Future placebo-controlled clinical trials will be required to establish safety and efficacy of probiotics in reducing fracture risk in people.
UR - http://www.scopus.com/inward/record.url?scp=84974534184&partnerID=8YFLogxK
U2 - 10.1172/JCI87430
DO - 10.1172/JCI87430
M3 - Comment/debate
C2 - 27111233
AN - SCOPUS:84974534184
SN - 0021-9738
VL - 126
SP - 2045
EP - 2048
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 6
ER -